Document Detail


Both autologous bone marrow mononuclear cells and peripheral blood progenitor cells therapies similarly improve ischemia in patients with diabetic foot in comparison with control treatment.
MedLine Citation:
PMID:  23390092     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIMS: The aim of our study was to compare the effect of bone marrow mononuclear cells (BMMNC) and peripheral blood progenitor cells (PBPC) therapy in patients with diabetic foot disease (DFD) and critical limb ischemia (CLI) unresponsive to revascularization with conservative therapy. METHODS: Twenty eight patients with DFD (17 treated by BMMNC and 11 by PBPC) were included into active group and 22 patients into control group without cell treatment. Transcutaneous oxygen pressure (TcPO(2) ) and rate of major amputation were compared between BMMNC, PBPC and control groups over 6 months as the main outcome measures; both cell therapy methods were also compared by the characteristics of cell suspensions. Possible adverse events were evaluated by changes of serum levels of angiogenic cytokines and retinal fundoscopic examination. RESULTS: TcPO(2) increased significantly (p < 0.05) compared to baseline in both active groups after 6 months, with no significant differences between BMMNC and PBPC groups; however no change of TcPO(2) in control group was observed. The rate of major amputation till 6 months was significantly lower in active cell therapy group compared to control group (11.1% vs. 50%, p = 0.0032), with no difference between BMMNC and PBPC. Number of injected CD34+ cells and serum levels of angiogenic cytokines after treatment did not significantly differ between BMMNC and PBPC. CONCLUSIONS: Our study showed superior benefit of BMMNC and PBPC treatment of CLI in patients with DFD when compared to conservative therapy. There was no difference between both cell therapy groups and no patient demonstrated signs of systemic vasculogenesis. Copyright © 2013 John Wiley & Sons, Ltd.
Authors:
M Dubsky; A Jirkovska; R Bem; V Fejfarova; L Pagacova; B Sixta; M Varga; S Langkramer; E Sykova; E B Jude
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-7
Journal Detail:
Title:  Diabetes/metabolism research and reviews     Volume:  -     ISSN:  1520-7560     ISO Abbreviation:  Diabetes Metab. Res. Rev.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883450     Medline TA:  Diabetes Metab Res Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 John Wiley & Sons, Ltd.
Affiliation:
Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Medical Faculty, Charles University, Prague, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human t...
Next Document:  Obstacles to the development of a neuroprotective therapy for Parkinson's disease.